Drugs / autologous bone marrow derived stem cells
autologous bone marrow derived stem cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03067870 | Nov 2016 → Dec 2021 | osteoarthritis, hip, osteoarthritis, knee, rheumatoid arthritis | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1 | NCT01082653 | Mar 2010 → May 2014 | amyotrophic lateral sclerosis | TCA Cellular Therapy | Suspended | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03067831 | Sep 2015 → Nov 2021 | Duchenne muscular dystrophy | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02016508 | Mar 2013 → Apr 2015 | age-related macular degeneration | Al-Azhar University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02479776 Comparator | May 2008 → Jan 2015 | dilated cardiomyopathy | Great Ormond Street Hospital for Children NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow derived stem cells | “Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.” NCT03067870 ↗4“Transplantation of purified autologous bone marrow-derived stem cells.” NCT03067831 ↗ “Injection of autologous bone marrow derived stem cells” NCT02479776 ↗ |
| Modality | Cell therapy | “autologous bone marrow-derived stem cells” NCT01082653 ↗ |
| Route | Intrathecal | “the investigational product will be injected into the patient's intrathecal space” NCT01082653 ↗ |